hester biosciences - report on stock fundamentals
DESCRIPTION
An analysis of the pharma company with special emphasis on fundamental principles. This gives a clean understanding of the financial strength of the company and how the company is ready for future growth. Simple illustrations have been used to replace traditional tables and graphs in analysis reports.lots more @ goodinvestory.comTRANSCRIPT
-
BSE Code : 524669NSE Code : Sector : PHARMACEUTICALSReport date : Thu Apr 24 06:52:20 EDT 2014
Industry overview
Market CapMarket Cap is the price ofall the outstandingcommon shares if we wereto buy it all at the currentprice
76.65 Cr
The benchmark companySun Pharma in thepharmaceuticals sector is1696 times the size ofHester Biosciences
Ultra Small Caps are achoice for people who canhandle very highvolatility/risk with very lowliquidity
1
-
Stock AnalysisGrowth AnalysisCompanies that have grown historically are more likely to exibit similar growth in the future. Readthe trends in the 4 year annualized profit growth, book value growth and sales growth shownbelow:
How good are the returns?RoE is the speed at which the company might grow without sorting to additional fund raising.RoCE is the growth speed, if the company used all the assets, including loans/preference shares.The 2-year and 4-year values give a reasonable assurance about the growth sustenance.
KEY
KEY
2
-
Piotroski ScoreSeperate Winners from LosersThe Piotroski scoring system is a nine point system to determine the strength of a firm's financialposition. The score was developed by an accounting professor out of Chicago named JosephPiotroski. If it scores an 8 or 9, then the fundamentals are great for the stock.
Score: 5/9
3
-
DISCLAIMER
This report is prepared by the good.inve.story. software and is not prepared by anactual person who has a CFA or any other certification.
good.inve.story. is still in BETA mode. So, please let us know if you find any errors.We would love to hear from you.
This report is based on information obtained from public sources and sourcesbelieved to be reliable, but no independent verification has been made nor is itsaccuracy or completeness guaranteed.
This report is not an advisory to buy or sell. Please buy only if you think, this is theright company at the right price and sell only if you dont see any potential forupside.
get more @ goodinvestory.com
4
Stock AnalysisGrowth AnalysisHow good are the returns?
Piotroski ScoreSeperate Winners from Losers